;PMID: 10875683
;source_file_918.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:41..196] = [t:41..196]
;2)section:[e:200..250] = [t:200..250]
;3)section:[e:254..336] = [t:254..336]
;4)section:[e:337..362] = [t:337..362]
;5)sentence:[e:366..368] = [t:366..368]
;6)sentence:[e:369..623] = [t:369..623]
;7)sentence:[e:624..626] = [t:624..626]
;8)sentence:[e:627..726] = [t:627..726]
;9)sentence:[e:727..942] = [t:727..942]
;10)sentence:[e:944..1100] = [t:944..1100]
;11)sentence:[e:1101..1103] = [t:1101..1103]
;12)sentence:[e:1104..1315] = [t:1104..1315]
;13)sentence:[e:1316..1318] = [t:1316..1318]
;14)sentence:[e:1319..1460] = [t:1319..1460]
;15)sentence:[e:1461..1463] = [t:1461..1463]
;16)sentence:[e:1464..1699] = [t:1464..1699]
;17)section:[e:1703..1748] = [t:1703..1748]

;section 0 Span:0..35
;Xenobiotica. 2000 May;30(5):503-13.
(SEC
  (FRAG (NNP:[0..11] Xenobiotica) (.:[11..12] .) (CD:[13..17] 2000)
        (NNP:[18..21] May) (CD:[21..25] ;30-LRB-) (CD:[25..26] 5)
        (-RRB-:[26..27] -RRB-) (CD:[27..31] :503) (HYPH:[31..32] -)
        (CD:[32..34] 13) (.:[34..35] .)))

;sentence 1 Span:41..196
;Identification of cytochrome P450 isoform involved in the metabolism of
;YM992, a  novel selective serotonin re-uptake inhibitor, in human liver
;microsomes.
;[59..82]:cyp450:"cytochrome P450 isoform"
;[113..118]:substance:"YM992"
;[129..168]:substance:"selective serotonin re-uptake inhibitor"
(SENT
  (NP-HLN
    (NP (NN:[41..55] Identification))
    (NP (IN:[56..58] of)
      (NP
        (NP
          (NML (NN:[59..69] cytochrome) (NN:[70..74] P450))
          (NN:[75..82] isoform))
        (VP (VBN:[83..91] involved)
          (NP (-NONE-:[91..91] *))
          (PP-CLR (IN:[92..94] in)
            (NP
              (NP (DT:[95..98] the) (NN:[99..109] metabolism))
              (PP (IN:[110..112] of)
                (NP
                  (NP (NN:[113..118] YM992))
                  (,:[118..119] ,)
                  (NP (DT:[120..121] a) (JJ:[123..128] novel)
                     (JJ:[129..138] selective)
                    (NML (NN:[139..148] serotonin) (AFX:[149..151] re)
                         (HYPH:[151..152] -) (NN:[152..158] uptake))
                    (NN:[159..168] inhibitor))))
              (,:[168..169] ,)
              (PP-LOC (IN:[170..172] in)
                (NP (JJ:[173..178] human) (NN:[179..184] liver)
                    (NNS:[185..195] microsomes))))))))
    (.:[195..196] .)))

;section 2 Span:200..250
;Noguchi K, Mera A, Watanabe T, Higuchi S, Chiba K.
(SEC
  (FRAG (NNP:[200..207] Noguchi) (NNP:[208..209] K) (,:[209..210] ,)
        (NNP:[211..215] Mera) (NNP:[216..217] A) (,:[217..218] ,)
        (NNP:[219..227] Watanabe) (NNP:[228..229] T) (,:[229..230] ,)
        (NNP:[231..238] Higuchi) (NNP:[239..241] S,) (NNP:[242..247] Chiba)
        (NNP:[248..250] K.)))

;section 3 Span:254..336
;Drug Metabolism Laboratories, Yamanouchi Pharmaceuticals Co., Ltd., Tokyo, 
;Japan.
(SEC
  (FRAG (NNP:[254..258] Drug) (NNP:[259..269] Metabolism)
        (NNP:[270..282] Laboratories) (,:[282..283] ,)
        (NNP:[284..294] Yamanouchi) (NNP:[295..310] Pharmaceuticals)
        (NNP:[311..314] Co.) (,:[314..315] ,) (NNP:[316..320] Ltd.)
        (,:[320..321] ,) (NNP:[322..327] Tokyo) (,:[327..328] ,)
        (NNP:[330..335] Japan) (.:[335..336] .)))

;section 4 Span:337..362
;noguchik@yamanouchi.co.jp
(SEC
  (FRAG (NN:[337..356] noguchik@yamanouchi) (NN:[356..362] .co.jp)))

;sentence 5 Span:366..368
;1.
(SENT
  (NP (LS:[366..368] 1.)))

;sentence 6 Span:369..623
;In vitro studies were conducted to identify the hepatic cytochrome P450 
;isoform involved in the metabolism of YM992, 
;((S)-2-[[(fluoro-4-indanyl)oxy]methyl]morpholine monohydrochloride), a novel 
;serotonin re-uptake inhibitor, in human liver microsomes.
;[425..449]:cyp450:"cytochrome P450  isoform"
;[480..485]:substance:"YM992"
;[489..554]:substance:"(S)-2-[[(fluoro-4-indanyl)oxy]methyl]morpholine
;monohydrochloride"
;[566..595]:substance:"serotonin re-uptake inhibitor"
(SENT
  (S
    (NP-SBJ-1
      (ADJP (FW:[369..371] In) (FW:[372..377] vitro))
      (NNS:[378..385] studies))
    (VP (VBD:[386..390] were)
      (VP (VBN:[391..400] conducted)
        (NP-1 (-NONE-:[400..400] *))
        (S-PRP
          (NP-SBJ (-NONE-:[400..400] *))
          (VP (TO:[401..403] to)
            (VP (VB:[404..412] identify)
              (NP
                (NP (DT:[413..416] the) (JJ:[417..424] hepatic)
                  
                  (NML (NN:[425..435] cytochrome) (NN:[436..440] P450))
                  (NN:[442..449] isoform))
                (VP (VBN:[450..458] involved)
                  (NP (-NONE-:[458..458] *))
                  (PP-CLR (IN:[459..461] in)
                    (NP
                      (NP (DT:[462..465] the) (NN:[466..476] metabolism))
                      (PP (IN:[477..479] of)
                        (NP
                          (NP
                            (NP (NN:[480..485] YM992))
                            (,:[485..486] ,)
                            (NP (-LRB-:[488..489] -LRB-)
                              
                               (NN:[489..536] -LRB-S-RRB--2--LSB--LSB--LRB-fluoro-4-indanyl-RRB-oxy-RSB-methyl-RSB-morpholine)
                               (NN:[537..554] monohydrochloride)
                              (-RRB-:[554..555] -RRB-)))
                          (,:[555..556] ,)
                          (NP (DT:[557..558] a) (JJ:[559..564] novel)
                            
                            (NML (NN:[566..575] serotonin) (AFX:[576..578] re)
                                 (HYPH:[578..579] -) (NN:[579..585] uptake))
                            (NN:[586..595] inhibitor))))
                      (,:[595..596] ,)
                      (PP (IN:[597..599] in)
                        (NP (JJ:[600..605] human) (NN:[606..611] liver)
                            (NNS:[612..622] microsomes))))))))))))
    (.:[622..623] .)))

;sentence 7 Span:624..626
;2.
(SENT
  (NP (LS:[624..626] 2.)))

;sentence 8 Span:627..726
;Microsomes prepared  from yeast expressing CYP1A1, CYP1A2 and CYP2D6
;effectively metabolized YM992.
;[670..676]:cyp450:"CYP1A1"
;[678..684]:cyp450:"CYP1A2"
;[689..695]:cyp450:"CYP2D6"
;[720..725]:substance:"YM992"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[627..637] Microsomes))
      (VP (VBN:[638..646] prepared)
        (NP (-NONE-:[646..646] *))
        (PP (IN:[648..652] from)
          (NP
            (NP (NN:[653..658] yeast))
            (VP (VBG:[659..669] expressing)
              (NP (NN:[670..676] CYP1A1) (,:[676..677] ,) (NN:[678..684] CYP1A2)
                  (CC:[685..688] and) (NN:[689..695] CYP2D6)))))))
    (ADVP (RB:[696..707] effectively))
    (VP (VBN:[708..719] metabolized)
      (NP (NN:[720..725] YM992)))
    (.:[725..726] .)))

;sentence 9 Span:727..942
;A  significant correlation was observed between the rate of YM992 metabolism
;and  7-ethoxyresorufin O-deethylation, CYP1A1/2 specific activity, in liver 
;microsomes from 16 individual donors (r2 = 0.628, p < 0.001).
;[787..792]:substance:"YM992"
;[809..826]:substance:"7-ethoxyresorufin"
;[843..849]:cyp450:"CYP1A1"
;[843..848]...[850..851]:cyp450:"CYP1A"..."2"
(SENT
  (S
    (NP-SBJ-4
      (NP (DT:[727..728] A) (JJ:[730..741] significant)
          (NN:[742..753] correlation))
      (PP-5 (-NONE-:[753..753] *ICH*)))
    (VP (VBD:[754..757] was)
      (VP (VBN:[758..766] observed)
        (NP-4 (-NONE-:[766..766] *))
        (PP-5 (IN:[767..774] between)
          (NP
            (NP (DT:[775..778] the) (NN:[779..783] rate))
            (PP (IN:[784..786] of)
              (NP
                (NP (NN:[787..792] YM992) (NN:[793..803] metabolism))
                (CC:[804..807] and)
                (NP
                  (NP (NN:[809..826] 7-ethoxyresorufin)
                      (NN:[827..841] O-deethylation))
                  (,:[841..842] ,)
                  (NP
                    (NP
                      (ADJP
                        (NML
                          (NML-1 (NN:[843..848] CYP1A))
                          (CD:[848..849] 1))
                        (ADJP-2 (-NONE-:[849..849] *P*)))
                      (NML-3 (-NONE-:[849..849] *P*)))
                    (SYM:[849..850] /)
                    (NP
                      (ADJP
                        (NML
                          (NML-1 (-NONE-:[850..850] *P*))
                          (CD:[850..851] 2))
                        (ADJP-2 (JJ:[852..860] specific)))
                      (NML-3 (NN:[861..869] activity)))))))))
        (,:[869..870] ,)
        (PP-LOC (IN:[871..873] in)
          (NP
            (NP (NN:[874..879] liver) (NNS:[881..891] microsomes))
            (PP (IN:[892..896] from)
              (NP (CD:[897..899] 16) (JJ:[900..910] individual)
                  (NNS:[911..917] donors)))))
        (PRN (-LRB-:[918..919] -LRB-)
          (S
            (S
              (NP-SBJ (NN:[919..921] r2))
              (VP (SYM:[922..923] =)
                (NP (CD:[924..929] 0.628))))
            (,:[929..930] ,)
            (S
              (NP-SBJ (NN:[931..932] p))
              (VP (SYM:[933..934] <)
                (NP (CD:[935..940] 0.001)))))
          (-RRB-:[940..941] -RRB-))))
    (.:[941..942] .)))

;sentence 10 Span:944..1100
;Alpha-naphtoflavone and isosafrole, CYP1A1/2 inhibitors, suppressed the 
;metabolism of YM992 in human liver microsomes in a concentration-dependent 
;manner.
;[944..963]:substance:"Alpha-naphtoflavone"
;[968..978]:substance:"isosafrole"
;[980..986]:cyp450:"CYP1A1"
;[980..985]...[987..988]:cyp450:"CYP1A"..."2"
;[989..999]:substance:"inhibitors"
;[1031..1036]:substance:"YM992"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[944..963] Alpha-naphtoflavone) (CC:[964..967] and)
          (NN:[968..978] isosafrole))
      (,:[978..979] ,)
      (NP
        (NP
          (NML
            (NML-1 (NN:[980..985] CYP1A))
            (CD:[985..986] 1))
          (NML-2 (-NONE-:[986..986] *P*)))
        (SYM:[986..987] /)
        (NP
          (NML
            (NML-1 (-NONE-:[987..987] *P*))
            (CD:[987..988] 2))
          (NML-2 (NNS:[989..999] inhibitors)))))
    (,:[999..1000] ,)
    (VP (VBD:[1001..1011] suppressed)
      (NP
        (NP (DT:[1012..1015] the) (NN:[1017..1027] metabolism))
        (PP (IN:[1028..1030] of)
          (NP (NN:[1031..1036] YM992))))
      (PP-LOC (IN:[1037..1039] in)
        (NP (JJ:[1040..1045] human) (NN:[1046..1051] liver)
            (NNS:[1052..1062] microsomes)))
      (PP-MNR (IN:[1063..1065] in)
        (NP (DT:[1066..1067] a)
          (ADJP (NN:[1068..1081] concentration) (HYPH:[1081..1082] -)
                (JJ:[1082..1091] dependent))
          (NN:[1093..1099] manner))))
    (.:[1099..1100] .)))

;sentence 11 Span:1101..1103
;3.
(SENT
  (NP (LS:[1101..1103] 3.)))

;sentence 12 Span:1104..1315
;The metabolism of YM992 in human liver microsomes was inhibited by 
;approximately 95% by antibodies which recognize both CYP1A1 and CYP1A2
;whereas  antibodies specific for CYP1A1 did not show inhibitory effects.
;[1122..1127]:substance:"YM992"
;[1186..1189]:quantitative-value:"95%"
;[1193..1203]:substance:"antibodies"
;[1225..1231]:cyp450:"CYP1A1"
;[1236..1242]:cyp450:"CYP1A2"
;[1252..1262]:substance:"antibodies"
;[1276..1282]:cyp450:"CYP1A1"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[1104..1107] The) (NN:[1108..1118] metabolism))
      (PP (IN:[1119..1121] of)
        (NP (NN:[1122..1127] YM992)))
      (PP-LOC (IN:[1128..1130] in)
        (NP (JJ:[1131..1136] human) (NN:[1137..1142] liver)
            (NNS:[1143..1153] microsomes))))
    (VP (VBD:[1154..1157] was)
      (VP (VBN:[1158..1167] inhibited)
        (NP-2 (-NONE-:[1167..1167] *))
        (PP-EXT (IN:[1168..1170] by)
          (NP
            (QP (RB:[1172..1185] approximately) (CD:[1186..1188] 95))
            (NN:[1188..1189] %)))
        (PP (IN:[1190..1192] by)
          (NP-LGS
            (NP (NNS:[1193..1203] antibodies))
            (SBAR
              (WHNP-1 (WDT:[1204..1209] which))
              (S
                (NP-SBJ-1 (-NONE-:[1209..1209] *T*))
                (VP (VBP:[1210..1219] recognize)
                  (NP (CC:[1220..1224] both) (NN:[1225..1231] CYP1A1)
                      (CC:[1232..1235] and) (NN:[1236..1242] CYP1A2)))))))
        (SBAR-ADV (IN:[1243..1250] whereas)
          (S
            (NP-SBJ
              (NP (NNS:[1252..1262] antibodies))
              (ADJP (JJ:[1263..1271] specific)
                (PP (IN:[1272..1275] for)
                  (NP (NN:[1276..1282] CYP1A1)))))
            (VP (VBD:[1283..1286] did) (RB:[1287..1290] not)
              (VP (VB:[1291..1295] show)
                (NP (JJ:[1296..1306] inhibitory) (NNS:[1307..1314] effects))))))))
    (.:[1314..1315] .)))

;sentence 13 Span:1316..1318
;4.
(SENT
  (NP (LS:[1316..1318] 4.)))

;sentence 14 Span:1319..1460
;The same  major metabolites, M6 and M7, were generated from YM992 after
;incubation with  human liver microsomes and recombinant human CYP1A2.
;[1335..1346]:substance:"metabolites"
;[1348..1350]:substance:"M6"
;[1355..1357]:substance:"M7"
;[1379..1384]:substance:"YM992"
;[1453..1459]:cyp450:"CYP1A2"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1319..1322] The) (JJ:[1323..1327] same) (JJ:[1329..1334] major)
          (NNS:[1335..1346] metabolites))
      (,:[1346..1347] ,)
      (NP (NN:[1348..1350] M6) (CC:[1351..1354] and) (NN:[1355..1357] M7)))
    (,:[1357..1358] ,)
    (VP (VBD:[1359..1363] were)
      (VP (VBN:[1364..1373] generated)
        (NP-1 (-NONE-:[1373..1373] *))
        (PP-CLR (IN:[1374..1378] from)
          (NP (NN:[1379..1384] YM992)))
        (PP-TMP (IN:[1385..1390] after)
          (NP
            (NP (NN:[1391..1401] incubation))
            (PP (IN:[1402..1406] with)
              (NP
                (NP (JJ:[1408..1413] human) (NN:[1414..1419] liver)
                    (NNS:[1420..1430] microsomes))
                (CC:[1431..1434] and)
                (NP (JJ:[1435..1446] recombinant) (JJ:[1447..1452] human)
                    (NN:[1453..1459] CYP1A2))))))))
    (.:[1459..1460] .)))

;sentence 15 Span:1461..1463
;5.
(SENT
  (NP (LS:[1461..1463] 5.)))

;sentence 16 Span:1464..1699
;These results suggest  that the metabolism of YM992 in human liver microsomes
;is mainly catalysed by  CYP1A2, and that YM992 might increase plasma
;concentration of concomitant drugs  metabolized by CYP1A2 due to competitive
;inhibition.
;[1510..1515]:substance:"YM992"
;[1566..1572]:cyp450:"CYP1A2"
;[1583..1588]:substance:"YM992"
;[1640..1645]:substance:"drugs"
;[1662..1668]:cyp450:"CYP1A2"
(SENT
  (S
    (NP-SBJ (DT:[1464..1469] These) (NNS:[1470..1477] results))
    (VP (VBP:[1478..1485] suggest)
      (SBAR
        (SBAR (IN:[1487..1491] that)
          (S
            (NP-SBJ-1
              (NP (DT:[1492..1495] the) (NN:[1496..1506] metabolism))
              (PP (IN:[1507..1509] of)
                (NP (NN:[1510..1515] YM992)))
              (PP-LOC (IN:[1516..1518] in)
                (NP (JJ:[1519..1524] human) (NN:[1525..1530] liver)
                    (NNS:[1531..1541] microsomes))))
            (VP (VBZ:[1542..1544] is)
              (ADVP (RB:[1545..1551] mainly))
              (VP (VBN:[1552..1561] catalysed)
                (NP-1 (-NONE-:[1561..1561] *))
                (PP (IN:[1562..1564] by)
                  (NP-LGS (NN:[1566..1572] CYP1A2)))))))
        (,:[1572..1573] ,) (CC:[1574..1577] and)
        (SBAR (IN:[1578..1582] that)
          (S
            (NP-SBJ (NN:[1583..1588] YM992))
            (VP (MD:[1589..1594] might)
              (VP (VB:[1595..1603] increase)
                (NP
                  (NP (NN:[1604..1610] plasma) (NN:[1611..1624] concentration))
                  (PP (IN:[1625..1627] of)
                    (NP
                      (NP (JJ:[1628..1639] concomitant) (NNS:[1640..1645] drugs))
                      (VP (VBN:[1647..1658] metabolized)
                        (NP (-NONE-:[1658..1658] *))
                        (PP (IN:[1659..1661] by)
                          (NP-LGS (NN:[1662..1668] CYP1A2)))))))
                (PP (IN:[1669..1672] due)
                  (PP (TO:[1673..1675] to)
                    (NP (JJ:[1676..1687] competitive)
                        (NN:[1688..1698] inhibition))))))))))
    (.:[1698..1699] .)))

;section 17 Span:1703..1748
;PMID: 10875683 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1703..1707] PMID) (::[1707..1708] :) (CD:[1709..1717] 10875683)
        (NN:[1718..1719] -LSB-) (NNP:[1719..1725] PubMed) (::[1726..1727] -)
        (NN:[1728..1735] indexed) (IN:[1736..1739] for)
        (NNP:[1740..1748] MEDLINE-RSB-)))
